Lewis Rubin

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Iloprost inhalation solution for the treatment of pulmonary arterial hypertension
    Henry H Hsu
    CoTherix, Inc, 5000 Shoreline Court, San Francisco, CA 94080, USA
    Expert Opin Pharmacother 6:1921-30. 2005
  2. ncbi Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension
    Carmelle V Remillard
    Department of Medicine, University of California San Diego, 9500 Gilman Dr, MC 0725, La Jolla, CA 92093 0725, USA
    Am J Physiol Cell Physiol 292:C1837-53. 2007
  3. ncbi Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
    Christopher P Denton
    Centre for Rheumatology, Royal Free Campus, University College Medical School, London, NW3 2PF, UK
    Arthritis Res Ther 13:114. 2011
  4. ncbi Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease
    Lewis J Rubin
    Division of Pulmonary and Critical Care Medicine, University of California San Diego, Campus Point Drive, La Jolla, California 92037 7381, USA
    Arthritis Res Ther 9:S10. 2007
  5. ncbi Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
    Lewis J Rubin
    Division of Pulmonary and Critical Care Medicine, University of California, San Diego School of Medicine, La Jolla, USA
    Chest 126:4S-6S. 2004
  6. ncbi Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
    Lewis J Rubin
    Division of Pulmonary and Critical Care Medicine, University of California, San Diego School of Medicine, La Jolla, USA
    Chest 126:7S-10S. 2004
  7. ncbi Treatment of pulmonary arterial hypertension due to scleroderma: challenges for the future
    Lewis J Rubin
    University of California, San Diego School of Medicine, 9300 Campus Point Drive, La Jolla, CA 92032, USA
    Rheum Dis Clin North Am 34:191-7; viii. 2008
  8. ncbi Pulmonary arterial hypertension: a look to the future
    Lewis J Rubin
    Pulmonary Vascular Center, University of California San Diego School of Medicine, La Jolla, California, USA
    J Am Coll Cardiol 43:89S-90S. 2004
  9. ncbi Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses
    Lewis J Rubin
    University of California, San Diego, CA, USA
    Proc Am Thorac Soc 3:601-7. 2006
  10. ncbi Perspective on the optimal endpoints for pulmonary arterial hypertension trials
    Lewis Rubin
    University of California, San Diego School of Medicine, La Jolla, California 92037, USA
    Curr Opin Pulm Med 16:S43-6. 2010

Detail Information

Publications75

  1. ncbi Iloprost inhalation solution for the treatment of pulmonary arterial hypertension
    Henry H Hsu
    CoTherix, Inc, 5000 Shoreline Court, San Francisco, CA 94080, USA
    Expert Opin Pharmacother 6:1921-30. 2005
    ..This article reviews iloprost inhalation solution, the most recently approved form of prostacyclin therapy that is delivered directly to the lungs by inhalation...
  2. ncbi Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension
    Carmelle V Remillard
    Department of Medicine, University of California San Diego, 9500 Gilman Dr, MC 0725, La Jolla, CA 92093 0725, USA
    Am J Physiol Cell Physiol 292:C1837-53. 2007
    ..g., nicotine and ET-1); 2) novel SNPs in KCNA5 are present in IPAH patients; and 3) SNPs in the promoter and translated regions of KCNA5 may underlie the altered expression and/or function of Kv1.5 channels in PASMC from IPAH patients...
  3. ncbi Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
    Christopher P Denton
    Centre for Rheumatology, Royal Free Campus, University College Medical School, London, NW3 2PF, UK
    Arthritis Res Ther 13:114. 2011
    ..Failure to take this into account may compromise progress in managing PAH in SSc...
  4. ncbi Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease
    Lewis J Rubin
    Division of Pulmonary and Critical Care Medicine, University of California San Diego, Campus Point Drive, La Jolla, California 92037 7381, USA
    Arthritis Res Ther 9:S10. 2007
    ....
  5. ncbi Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
    Lewis J Rubin
    Division of Pulmonary and Critical Care Medicine, University of California, San Diego School of Medicine, La Jolla, USA
    Chest 126:4S-6S. 2004
  6. ncbi Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
    Lewis J Rubin
    Division of Pulmonary and Critical Care Medicine, University of California, San Diego School of Medicine, La Jolla, USA
    Chest 126:7S-10S. 2004
  7. ncbi Treatment of pulmonary arterial hypertension due to scleroderma: challenges for the future
    Lewis J Rubin
    University of California, San Diego School of Medicine, 9300 Campus Point Drive, La Jolla, CA 92032, USA
    Rheum Dis Clin North Am 34:191-7; viii. 2008
    ..It also provides a glimpse into the future, based on recent developments in the field that hold promise for enhancing the treatment of this disease...
  8. ncbi Pulmonary arterial hypertension: a look to the future
    Lewis J Rubin
    Pulmonary Vascular Center, University of California San Diego School of Medicine, La Jolla, California, USA
    J Am Coll Cardiol 43:89S-90S. 2004
    ..This summary provides a brief overview of future directions in the field...
  9. ncbi Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses
    Lewis J Rubin
    University of California, San Diego, CA, USA
    Proc Am Thorac Soc 3:601-7. 2006
    ..Continued research and clinical trials investigating possible applications of new medical treatments are required...
  10. ncbi Perspective on the optimal endpoints for pulmonary arterial hypertension trials
    Lewis Rubin
    University of California, San Diego School of Medicine, La Jolla, California 92037, USA
    Curr Opin Pulm Med 16:S43-6. 2010
    ..Time to clinical worsening (TTCW) may represent an alternative, and although it is being considered as a primary endpoint in future trials, it will ultimately require refinement before it can be broadly applied...
  11. ncbi Bosentan: a dual endothelin receptor antagonist
    Lewis J Rubin
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California at San Diego, School of Medicine, 9300 Campus Point Drive, 7372, La Jolla, CA 92037, USA
    Expert Opin Investig Drugs 11:991-1002. 2002
    ....
  12. ncbi Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study
    Lewis J Rubin
    Department of Medicine, University of California at San Diego, UCSD Medical Center Thornton, 9300 Campus Point Dr MC 7372, La Jolla, CA 92037, USA
    Chest 140:1274-83. 2011
    ..The long-term safety and tolerability of sildenafil treatment of pulmonary arterial hypertension (PAH) were assessed...
  13. ncbi Metabolic dysfunction in the pathogenesis of pulmonary hypertension
    Lewis J Rubin
    University of California, San Diego, La Jolla, CA 92093, USA
    Cell Metab 12:313-4. 2010
    ..2010) found that increased fatty acid oxidation and a shift in the glycolysis/glucose oxidation ratio may be central to the pathogenesis of this process, suggesting that these abnormalities comprise novel treatment targets...
  14. ncbi Bosentan therapy for pulmonary arterial hypertension
    Lewis J Rubin
    Division of Pulmonary and Critical Care Medicine, University of California at San Diego, La Jolla 92037 1330, USA
    N Engl J Med 346:896-903. 2002
    ..The present trial investigated the effect of bosentan on exercise capacity in a larger number of patients and compared two doses...
  15. ncbi Pulmonary arterial hypertension
    Lewis J Rubin
    University of California, San Diego, School of Medicine, 9300 Campus Point Drive, La Jolla, CA 92037, USA
    Proc Am Thorac Soc 3:111-5. 2006
    ..The article reviews the classification of diseases associated with PAH, the current understanding of its pathogenesis, and the contemporary approach to therapy...
  16. ncbi Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension
    Nick H S Kim
    Division of Pulmonary and Critical Care Medicine, University of California, San Diego, La Jolla, CA 92037-1300, USA
    J Cardiovasc Pharmacol Ther 7:9-19. 2002
    ..Current classification and management of PAH are reviewed, along with the promise of greatly improved treatment generated by recent and ongoing clinical trials using ERAs...
  17. ncbi Preoperative partitioning of pulmonary vascular resistance correlates with early outcome after thromboendarterectomy for chronic thromboembolic pulmonary hypertension
    Nick H S Kim
    University of California, San Diego, 9300 Campus Point Dr, M/C 7381, La Jolla, CA 92037-1300, USA
    Circulation 109:18-22. 2004
    ..Patients with CTEPH and Rup value <60% appear to be at highest risk...
  18. ncbi The right ventricle in pulmonary hypertension
    Kelly M Chin
    Division of Pulmonary and Critical Care Medicine, University of California, San Diego School of Medicine, La Jolla, California, USA
    Coron Artery Dis 16:13-8. 2005
    ..The article will review the normal structure and function of the right ventricle and summarize the impact of PAH and its treatments on right ventricular function...
  19. ncbi Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension
    Mehran Mandegar
    Department of Medicine, School of Medicine, University of California, San Diego, La Jolla 92093, USA
    Microvasc Res 68:75-103. 2004
    ....
  20. ncbi Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes
    Naomi Kunichika
    Department of Medicine, University of California, San Diego, La Jolla, California, USA
    Am J Respir Crit Care Med 170:1101-7. 2004
    ..The greater effect of bosentan on IPAH-PASMCs than on normal PASMCs suggests that increased TRPC6 expression and function may be involved in the overgrowth of PASMCs in patients with IPAH...
  21. ncbi Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension
    Richard N Channick
    UCSD Medical Center, La Jolla, California 92037, USA
    J Am Coll Cardiol 48:1433-7. 2006
    ..This study evaluated the safety and efficacy of inhaled treprostinil as add-on therapy to oral bosentan in patients with pulmonary arterial hypertension (PAH)...
  22. ncbi Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension
    Ying Yu
    Department of Medicine, School of Medicine, University of California at San Diego, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 101:13861-6. 2004
    ..TRPC channel overexpression may be partially responsible for the increased PASMC proliferation and pulmonary vascular medial hypertrophy in IPAH patients...
  23. ncbi Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension
    Ronald J Oudiz
    LA Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California, USA
    J Am Coll Cardiol 54:1971-81. 2009
    ..This study evaluated the safety and efficacy of ambrisentan for a period of 2 years in patients with pulmonary arterial hypertension (PAH)...
  24. ncbi Endothelin receptor antagonists in pulmonary arterial hypertension
    Richard N Channick
    Pulmonary and Critical Care Division, University of California, San Diego, California, USA
    J Am Coll Cardiol 43:62S-67S. 2004
    ..The selective endothelin receptor-A antagonists sitaxsentan and ambrisentan are currently undergoing investigation...
  25. ncbi Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol
    David B Badesch
    Department of Medicine, University of Colorado Denver, Denver, Colorado, USA
    J Rheumatol 36:2244-9. 2009
    ..v.) infusion in an uncontrolled open-label 3-year extension study following an initial randomized, controlled 12-week study...
  26. ncbi Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension
    Weijuan Yao
    Division of Pulmonary and Critical Care Medicine, Dept of Medicine, MTF 252, Univ of California, San Diego, 9200 Gilman Dr, MC 0725, La Jolla, CA 92093 0725, USA
    Am J Physiol Lung Cell Mol Physiol 296:L870-8. 2009
    ..It is possible that the microenvironment provided by thromboemboli may promote these putative progenitor cells to differentiate and enhance intimal remodeling...
  27. ncbi Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension
    Nick H Kim
    Pulmonary Vascular Center, University of California, San Diego, CA, La Jolla 92037, USA
    Chest 124:1612-5. 2003
    ..7 years (range, 2.4 to 13.5 years) CONCLUSION: Epoprostenol may sufficiently reverse the pathogenic process in select patients with PAH to allow a transition to less complex and less invasive treatment modalities...
  28. ncbi Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?
    Kelly M Chin
    Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, St. Paul University Hospital, Dallas, TX, USA
    Chest 130:1657-63. 2006
    ..5; p < 0.0001) more likely to have used stimulants than patients with CTEPH. CONCLUSIONS: Patients with idiopathic PAH are significantly more likely to have used stimulants than patients with other forms of pulmonary hypertension...
  29. ncbi Chronic thromboembolic pulmonary hypertension
    Timothy L Williamson
    Division of Pulmonary and Critical Care Medicine, University of California, San Diego, La Jolla 92037, USA
    Prog Cardiovasc Dis 45:203-12. 2002
    ..Definitive treatment requires surgical resection of thromboembolic material. The role of medical therapy remains to be defined...
  30. ncbi Successful liver transplantation in a child with severe portopulmonary hypertension treated with epoprostenol
    Ahmed Laving
    Division of Pediatric Gastroenterology and Nutrition, University of California, San Diego, California 92103, USA
    J Pediatr Gastroenterol Nutr 41:466-8. 2005
  31. ncbi Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)
    Dinesh Khanna
    David Geffen School at University of California, Los Angeles, CA, USA
    J Rheumatol 36:2356-61. 2009
    ..CRISS and EPOSS are being developed through the OMERACT process. Through Delphi process and literature review significant progress has been made for both indices, and prospective data are being collected...
  32. ncbi A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension
    Ying Yu
    Department of Medicine, University of California, San Diego, La Jolla, CA 92093 0725, USA
    Circulation 119:2313-22. 2009
    ..This study sought to identify single-nucleotide polymorphisms (SNPs) in the TRPC6 gene promoter that are associated with IPAH and have functional significance in regulating TRPC6 activity in PASMCs...
  33. ncbi Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group
    Jerome Avouac
    Division of Rheumatology, Department of Medicine, David Geffen School at UCLA, 1000 Veteran Avenue, Room 32 59, Los Angeles, CA 90095 1670, USA
    Ann Rheum Dis 69:1360-3. 2010
    ..To assess the validity of the 6 min walk test (6MWT) in pulmonary arterial hypertension secondary to systemic sclerosis (PAH-SSc) according to the OMERACT filter...
  34. ncbi Upregulation of Na+/Ca2+ exchanger contributes to the enhanced Ca2+ entry in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension
    Shen Zhang
    Dept of Medicine, University of California, San Diego, La Jolla, CA 92093 0725, USA
    Am J Physiol Cell Physiol 292:C2297-305. 2007
    ..These observations indicate that the upregulated NCX1 and enhanced Ca(2+) entry via the reverse mode of Na(+)/Ca(2+) exchange are an additional mechanism responsible for the elevated [Ca(2+)](cyt) in PASMC from IPAH patients...
  35. ncbi Evaluation and management of the patient with pulmonary arterial hypertension
    Lewis J Rubin
    University of California, San Diego, Medical Center, La Jolla, California 92037-7381, USA
    Ann Intern Med 143:282-92. 2005
    ..In this review, the authors present approaches to the diagnosis and management of pulmonary arterial hypertension, using a hypothetical case to highlight the key management points...
  36. ncbi Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells
    Shen Zhang
    Dept of Medicine, UCSD Medical Center, 200 West Arbor Dr, San Diego, CA 92103 8382, USA
    Am J Physiol Lung Cell Mol Physiol 285:L740-54. 2003
    ..Inhibition of BMP-induced PASMC apoptosis in PPH patients may play an important role in the development of pulmonary vascular medial hypertrophy in these patients...
  37. ncbi Nitric oxide induces apoptosis by activating K+ channels in pulmonary vascular smooth muscle cells
    Stefanie Krick
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California School of Medicine, 200 W. Arbor Dr, San Diego, CA 92103-8382, USA
    Am J Physiol Heart Circ Physiol 282:H184-93. 2002
    ..The resulting increase in K+ efflux leads to cytosolic K+ loss and eventual apoptosis volume decrease and apoptosis. NO-induced apoptosis may also be related to mitochondrial membrane depolarization in PASMC...
  38. ncbi Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective
    C Gregory Elliott
    Department of Medicine, Division of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, UT 84157 7000, USA
    Chest 137:85S-94S. 2010
    ..Political, economic, and cultural barriers must be identified and overcome as part of any strategic plan. Global education should include training objectives for generalist, non-PH specialist, and PH specialist physicians...
  39. ncbi Prednisolone inhibits PDGF-induced nuclear translocation of NF-kappaB in human pulmonary artery smooth muscle cells
    Aiko Ogawa
    Department of Medicine, University of California, San Diego, La Jolla, CA 92093 0725, USA
    Am J Physiol Lung Cell Mol Physiol 295:L648-57. 2008
    ....
  40. ncbi Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension
    Anastasia Anthi
    Vascular Medicine Branch, Clinical Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 2089, USA
    Am J Respir Crit Care Med 175:1272-9. 2007
    ..Although pulmonary hypertension (PH) is a common complication of sickle cell disease (SCD) associated with high mortality, there exist few data characterizing hemodynamics and cardiopulmonary function in this population...
  41. ncbi Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines
    David B Badesch
    University of Colorado Health Sciences Center, Box C 272, 4200 E Ninth Ave, Denver, CO 80262, USA
    Chest 131:1917-28. 2007
    ..Due to the complexity of the diagnostic evaluation required and the treatment options available, referral of patients with PAH to a specialized center continues to be strongly recommended...
  42. ncbi Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels
    Kelly M Chin
    Department of Internal Medicine, University of Texas Southwestern Pulmonary Hypertension Program, 5909 Harry Hines Blvd, Dallas, TX 75235 9254, USA
    Chest 132:786-92. 2007
    ....
  43. ncbi High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension
    Diana Bonderman
    Department of Internal Medicine II, Division of Cardiology, University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Thromb Haemost 90:372-6. 2003
    ..0001) and PAH patients (22%, p = 0.022). We can conclude that elevated plasma FVIII is the first prothrombotic factor identified in a large proportion of CTEPH patients...
  44. ncbi Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study
    Olivier Sitbon
    Service de Pneumologie Réanimation Respiratoire, Hopital Antoine Beclere, 157, Avenue de la Porte Trivaux, F 92141 Clamart Cedex, France
    Chest 124:247-54. 2003
    ..We report on the long-term safety and efficacy of bosentan treatment in patients with pulmonary arterial hypertension (PAH)...
  45. ncbi Pulmonary arterial hypertension
    Kelly M Chin
    Department of Internal Medicine, Division of Pulmonary and Critical Care, University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA
    J Am Coll Cardiol 51:1527-38. 2008
    ..The purpose of this review is to describe the current state of evidence for the diagnosis, prognosis, and treatment of the patient with PAH...
  46. ncbi Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis
    Oliver Distler
    University Hospital Zurich, Zurich, Switzerland
    Arthritis Rheum 59:867-75. 2008
    ..The aim of the present study was to establish an expert consensus regarding which outcome measures are most appropriate for clinical trials in PAH-SSc...
  47. ncbi Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial
    Gerald Simonneau
    Service de Pneumologie, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Ann Intern Med 149:521-30. 2008
    ..Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension...
  48. ncbi Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies
    Robert Voswinckel
    Department of Internal Medicine, University Hospital Giessen, Giessen, Germany
    J Am Coll Cardiol 48:1672-81. 2006
    ..CONCLUSIONS: Inhaled treprostinil exerts sustained pulmonary vasodilation with excellent tolerability at relatively low doses and may be inhaled in a few breaths...
  49. ncbi Epoprostenol therapy as a bridge to pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension
    Kim M Kerr
    Chest 123:319-20. 2003
  50. ncbi Inhaled iloprost for severe pulmonary hypertension
    Horst Olschewski
    Department of Internal Medicine II, University Clinic, Giessen, Germany
    N Engl J Med 347:322-9. 2002
    ..CONCLUSIONS: Inhaled iloprost is an effective therapy for patients with severe pulmonary hypertension...
  51. ncbi Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial
    Gerald Simonneau
    Division of Pulmonary and Critical Care Medicine, Antoine Beclere Hospital, Clamart, Paris Sud University, Clamart, France
    Am J Respir Crit Care Med 165:800-4. 2002
    ..We conclude that chronic subcutaneous infusion of treprostinil is an effective treatment with an acceptable safety profile in patients with pulmonary arterial hypertension...
  52. ncbi Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    J Am Coll Cardiol 43:81S-88S. 2004
    ..Combination therapy can be attempted in selected cases. Both balloon atrial septostomy and lung transplantation are indicated for refractory patients or where medical treatment is unavailable...
  53. ncbi Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Circulation 117:3010-9. 2008
    ..Ambrisentan is a propanoic acid-based, A-selective endothelin receptor antagonist for the once-daily treatment of pulmonary arterial hypertension...
  54. ncbi Ambrisentan therapy for pulmonary arterial hypertension
    Nazzareno Galie
    University of Bologna, Bologna, Italy
    J Am Coll Cardiol 46:529-35. 2005
    ..The purpose of this study was to examine the efficacy and safety of four doses of ambrisentan, an oral endothelin type A receptor-selective antagonist, in patients with pulmonary arterial hypertension (PAH)...
  55. ncbi Sildenafil citrate therapy for pulmonary arterial hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    N Engl J Med 353:2148-57. 2005
    ....
  56. ncbi Epoprostenol and nesiritide in pulmonary hypertension
    Lewis J Rubin
    Chest 127:1870. 2005
  57. ncbi Chronic thromboembolic pulmonary hypertension
    Marius M Hoeper
    Department of Respiratory Medicine, Hannover Medical School, 30623 Hannover, Germany
    Circulation 113:2011-20. 2006
  58. ncbi Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension
    Vallerie V McLaughlin
    The University of Michigan Health System, Ann Arbor, Michigan, USA
    Am J Respir Crit Care Med 174:1257-63. 2006
    ..Small, open-label studies suggest that combinations of existing therapies may be effective for pulmonary arterial hypertension (PAH)...
  59. ncbi Pathogenesis of pulmonary arterial hypertension: the need for multiple hits
    Jason X-J Yuan
    Circulation 111:534-8. 2005
  60. ncbi Endothelin-1 and the pulmonary vascular response to altitude: a new therapeutic target?
    Lewis J Rubin
    Circulation 114:1350-1. 2006
  61. ncbi Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease
    Ronald J Oudiz
    Research and Education Institute, Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Chest 126:420-7. 2004
    ..To assess the efficacy and safety of continuous subcutaneous infusion of treprostinil, a stable prostacyclin analogue, for treating pulmonary arterial hypertension (PAH) in patients with connective tissue disease (CTD)...
  62. ncbi Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure
    Norbert F Voelkel
    Pulmonary Hypertension Center, University of Colorado at Denver and Health Sciences Center, 4200 E Ninth Ave, MC: C272, Denver, CO 80262, USA
    Circulation 114:1883-91. 2006
  63. ncbi Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers
    Marius M Hoeper
    Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
    J Am Coll Cardiol 48:2546-52. 2006
    ..This study sought to assess the risks associated with right heart catheter procedures in patients with pulmonary hypertension...
  64. ncbi Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery
    Lucie H Clapp
    Centre for Clinical Pharmacology, Department of Medicine, University College London, Rayne Institute 4th Floor, 5 University Street, London W1C 6JJ, United Kingdom
    Am J Respir Cell Mol Biol 26:194-201. 2002
    ..Thus, PGI(2) analogs potently inhibit proliferation of human pulmonary artery, probably via a cAMP-dependent pathway, although cAMP elevation in itself is not a good predictor of antiproliferative potency...
  65. ncbi Sildenafil for enhanced performance at high altitude?
    Lewis J Rubin
    Ann Intern Med 141:233-5. 2004
  66. ncbi New treatments for pulmonary arterial hypertension
    Marius M Hoeper
    Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
    Am J Respir Crit Care Med 165:1209-16. 2002
  67. ncbi Management following pulmonary thromboendarterectomy: experience versus evidence
    Nick H S Kim
    Crit Care Med 33:2132-3. 2005
  68. ncbi Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents
    Lewis J Rubin
    Am J Respir Crit Care Med 166:1308-9. 2002
  69. ncbi Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension
    Vallerie V McLaughlin
    Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    J Cardiovasc Pharmacol 41:293-9. 2003
    ..Subcutaneous treprostinil has favorable hemodynamic effects when given acutely and in the short term. Treprostinil can be given safely to an ambulatory patient with a novel subcutaneous delivery pump system...
  70. ncbi Clinical classification of pulmonary hypertension
    Gerald Simonneau
    Department of Pulmonary and Critical Medicine, University of Paris Sud, Paris, France
    J Am Coll Cardiol 43:5S-12S. 2004
    ....
  71. ncbi Temporal trends and drug exposures in pulmonary hypertension: an American experience
    Alexander M Walker
    Harvard School of Public Health, Boston, MA, USA
    Am Heart J 152:521-6. 2006
    ..We also studied whether use of anorexigens and other drugs differed among patients with pulmonary hypertension of different etiologies...
  72. ncbi BMPR2 mutation and outcome in pulmonary arterial hypertension: clinical relevance to physicians and patients
    Lewis J Rubin
    Am J Respir Crit Care Med 177:1300-1. 2008
  73. ncbi Sildenafil for pulmonary arterial hypertension associated with connective tissue disease
    David B Badesch
    Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Rheumatol 34:2417-22. 2007
    ..The phosphodiesterase-5 inhibitor sildenafil citrate enhances vasodilatation, has antiproliferative effects, and is effective in the treatment of PAH. We examined the efficacy and safety of oral sildenafil in patients with PAH-CTD...